The estimated Net Worth of Kevin Ctang Capital Partner... is at least $50.3 Milion dollars as of 30 January 2020. Kevin Partner owns over 169,770 units of La Jolla Pharmaceutical Co stock worth over $50,259,746 and over the last 10 years Kevin sold LJPC stock worth over $0.
Kevin has made over 23 trades of the La Jolla Pharmaceutical Co stock since 2014, according to the Form 4 filled with the SEC. Most recently Kevin bought 169,770 units of LJPC stock worth $1,147,645 on 30 January 2020.
The largest trade Kevin's ever made was buying 2,971,682 units of La Jolla Pharmaceutical Co stock on 9 January 2020 worth over $17,443,773. On average, Kevin trades about 324,403 units every 85 days since 2014. As of 30 January 2020 Kevin still owns at least 8,080,345 units of La Jolla Pharmaceutical Co stock.
You can see the complete history of Kevin Partner stock trades at the bottom of the page.
Over the last 21 years, insiders at La Jolla Pharmaceutical Co have traded over $13,460,170 worth of La Jolla Pharmaceutical Co stock and bought 11,640,515 units worth $137,250,039 . The most active insiders traders include Advisors Llcperceptive Life..., James N Topper a Woodlands Health Ventures F.... On average, La Jolla Pharmaceutical Co executives and independent directors trade stock every 63 days with the average trade being worth of $1,249,971. The most recent stock trade was executed by Craig A Johnson on 8 July 2022, trading 12,000 units of LJPC stock currently worth $47,160.
La Jolla Pharmaceutical Company is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases. In December 2017, GIAPREZA™ (angiotensin II) was approved by the U.S. Food and Drug Administration (FDA) as a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. In August 2019, GIAPREZA was approved by the European Commission (EC) for the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies. LJPC-0118 (artesunate) is La Jolla's investigational product for the treatment of severe malaria.
La Jolla Pharmaceutical Co executives and other stock owners filed with the SEC include: